ArticleTranslational vision science & technology2026
Identification of Ocular and Systemic Predictors and Development of a Prediction Model in Ocular Myasthenia Gravis.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Predicting patients with ocular myasthenia gravis (OMG) achieving minimal manifestation status (MMS) or better is crucial for guiding treatment decisions. Prognostic models are becoming increasingly popular in the medical field due to their high accuracy. This study aimed to develop a clinical tool based on both ocular and systemic factors. Methods: We reviewed patients from our hospital from 2020 to 2023. Logistic and Least Absolute Shrinkage and Selection Operator (LASSO) regressions were applied to determine key predictors. A logistic nomogram model was constructed based on the selected factors. The model's performance was rigorously evaluated through internal validation for discrimination, calibration, and clinical utility. Results: Among 216 patients, 126 individuals were included in the study. A total of 61 patients (48.4%) achieved MMS or better status in the 1-year outcome. Five key variables were selected to conduct the prognostic model, including ocular deviation angle, duration, antibody, corticosteroid therapy, and thyroid ultrasound. The area under the curve (AUC) was 0.889 (95% confidence interval [CI] = 0.832-0.947), demonstrating a good performance. The calibration curves also showed excellent agreement between predicted and observed probabilities in both training and validation cohorts. Conclusions: This study provides a clinically applicable predictive model, which accurately identifies patients with OMG likely to achieve MMS or better status within 1 year. The model is predictive of individual patients with great performance, thereby increasing clinical confidence and utility. Translational Relevance: This study translates specific ocular examination findings into a practical prognostic tool. The developed model directly assists clinicians in identifying patients with OMG with a high probability of achieving remission within 1 year, thereby informing personalized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.